Latest market price
15.55
-2.63-14.47%
Earnings
Down 14.5% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -4.24 | Insider Own | 36.04% | Shs Outstand | 88.41M | Perf Week | -24.37% |
| Market Cap | 1.37B | Forward P/E | — | EPS next Y | -2.43 | Insider Trans | -1.47% | Shs Float | 60.84M | Perf Month | -34.19% |
| Enterprise Value | 811.73M | PEG | — | EPS next Q | -0.55 | Short Float | 12.23% | Perf Quarter | -41.32% | ||
| Income | -349.00M | P/S | — | EPS this Y | — | Short Ratio | 6.68 | Perf Half Y | -47.55% | ||
| Sales | 0.00 | P/B | 2.49 | EPS next Y | — | ROA | -52.34% | Short Interest | 7.44M | Perf YTD | -57.15% |
| Book/sh | 6.23 | P/C | 2.08 | EPS next 5Y | — | ROE | -57.97% | 52W High | 47.66 -67.37% | Perf Year | -62.18% |
| Cash/sh | 7.48 | P/FCF | — | EPS past 3/5Y | — | ROIC | -57.17% | 52W Low | 15.42 0.84% | Perf 3Y | 93.17% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 9.35% 6.35% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.48 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 34.46 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 23.79 | Recom | 2.13 |
| Dividend Gr. 3/5Y | — | Current Ratio | 34.46 | EPS Q/Q | -331.82% | SMA20 | -25.84% | Beta | 1.56 | Target Price | 29.00 |
| Payout | 0.00% | Debt/Eq | 0.18 | Sales Q/Q | — | SMA50 | -36.72% | Rel Volume | 3.42 | Prev Close | 18.18 |
| Employees | 76 | LT Debt/Eq | 0.18 | Earnings | Nov 04 | SMA200 | -42.22% | Avg Volume | 1.34M | Price | 15.55 |
| IPO Date | Feb 10, 2023 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -419.53% — | Net Debt/EBITDA | — | Volume | 4,588,902 | Change | -14.47% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-11-26 | Initiated | UBS | Neutral | $29 |
| Mar-13-26 | Reiterated | Jefferies | Hold | $30 |
| Mar-10-26 | Reiterated | H.C. Wainwright | Buy | $52 → $56 |
| Dec-19-25 | Reiterated | Stifel Nicolaus | $45 → $52 | |
| Oct-30-25 | Reiterated | HC Wainwright & Co. | Buy | $42 → $52 |
| May-14-25 | Reiterated | Guggenheim | Buy | $52 → $48 |
| Apr-02-25 | Reiterated | HC Wainwright & Co. | Buy | $42 |
| Apr-02-24 | Reiterated | Goldman Sachs | $30 |
Latest News· Times ET
Oct-28-26
Oct-28-2604:05PM
07:05AM
Oct-22-26
Oct-22-2606:40PM
Oct-19-26
Oct-19-2604:05PM
Oct-12-26
Oct-12-2607:26PM
05:33AM
Oct-09-26
Oct-09-2609:00AM
Oct-04-26
Oct-04-2608:02AM
Oct-02-26
Oct-02-2604:30PM
Oct-01-26
Oct-01-2604:05PM
Sep-29-26
Sep-29-2604:05PM
Sep-25-26
Sep-25-2604:08AM
Sep-24-26
Sep-24-2604:05PM
Sep-23-26
Company
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 70 | 39 | 24 | 14 | — | — | — | |
| Research and Development | 300 | 132 | 169 | 70 | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | 1 | — | — | — | |
| Operating Income | -370 | -171 | -192 | -85 | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 21 | 16 | 15 | 13 | — | — | — | |
| Net Income Before Taxes | -349 | -155 | -178 | -72 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -349 | -155 | -178 | -72 | — | — | — | |
| Net Income From Continuing Operations | -349 | -155 | -178 | -72 | — | — | — | |
| Net Income | -349 | -155 | -178 | -72 | — | — | — | |
| EPS (Recurring) | -4.24 | -2.29 | -3.66 | -1.99 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.24 | -2.29 | -3.66 | -1.99 | — | — | — | |
| EPS (Diluted) | -4.24 | -2.29 | -3.66 | -1.99 | — | — | — | |
| EBITDA | -349 | -155 | -178 | -72 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 85 | 68 | 49 | 36 | — | — | — | |
| Market Capitalization | 1,322 | 2,468 | 603 | 310 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Congleton Jon | Chief Executive Officer | Sep 30 '26 | Sale | 25.46 | 75,000 | 1,909,665 | 528,621 | Oct 02 |
| Slingsby Brian Taylor | Director | Sep 22 '26 | Sale | 28.81 | 104,320 | 3,005,303 | 7,805,718 | Sep 24 |
| Warren Eric | Chief Commercial Officer | Sep 21 '26 | Option Exercise | 13.24 | 7,438 | 98,479 | 45,838 | Sep 22 |
| Warren Eric | Chief Commercial Officer | Sep 21 '26 | Sale | 28.12 | 7,438 | 209,136 | 38,400 | Sep 22 |
| Karydas Daphne | Director | Sep 15 '26 | Option Exercise | 12.02 | 3,000 | 36,060 | 9,200 | Sep 17 |
| Karydas Daphne | Director | Sep 15 '26 | Sale | 28.58 | 3,000 | 85,740 | 6,200 | Sep 17 |
| Warren Eric | Chief Commercial Officer | Aug 21 '26 | Option Exercise | 13.24 | 7,437 | 98,466 | 45,837 | Aug 25 |
| Warren Eric | Chief Commercial Officer | Aug 21 '26 | Sale | 25.98 | 7,437 | 193,189 | 38,400 | Aug 25 |
| Rodman David Malcom | Chief Medical Officer | Aug 10 '26 | Option Exercise | 16.00 | 2,170 | 34,720 | 53,554 | Aug 12 |
| Rodman David Malcom | Chief Medical Officer | Aug 10 '26 | Sale | 27.09 | 2,170 | 58,785 | 51,384 | Aug 12 |
| Warren Eric | Chief Commercial Officer | Jul 21 '26 | Option Exercise | 13.24 | 7,438 | 98,479 | 45,838 | Jul 23 |
| Warren Eric | Chief Commercial Officer | Jul 21 '26 | Sale | 26.87 | 7,438 | 199,885 | 38,400 | Jul 23 |
| Rodman David Malcom | Chief Medical Officer | Jul 17 '26 | Option Exercise | 15.44 | 416 | 6,423 | 51,800 | Jul 20 |
| Rodman David Malcom | Chief Medical Officer | Jul 17 '26 | Sale | 26.53 | 416 | 11,036 | 51,384 | Jul 20 |
| Rodman David Malcom | Chief Medical Officer | Jul 15 '26 | Sale | 26.61 | 6,349 | 168,955 | 51,384 | Jul 15 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.